Skip to content

Technology Delivered Diabetes-Modified Behavioral Activation Treatment

Technology Delivered Diabetes-Modified Behavioral Activation Treatment for AAs With T2DM

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03593694
Acronym
TECHDMBAT
Enrollment
30
Registered
2018-07-20
Start date
2017-11-06
Completion date
2019-04-30
Last updated
2024-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Brief summary

The overarching goal of this proposal is to test the efficacy of a multi-component, high intensity intervention, technology delivered, diabetes-modified behavioral activation treatment (TECH DM-BAT) that incorporates: 1) diabetes education; 2) home telemonitoring; and 3) diabetes modified behavioral activation, delivered by nurses via smartphones is effective in improving metabolic control in African Americans with poorly controlled type 2 diabetes.

Detailed description

Diabetes Mellitus is highly prevalent in the United States (CDC 2014) and African Americans (AA) are disproportionately affected and have higher prevalence, poorer metabolic control and greater risk for complications and death compared to White Americans. Evidence from the literature show that effective interventions for AAs with Type 2 Diabetes Mellitus (T2DM) have multiple components including: education and skills training, nurse case management, and maintain high intensity. However, few large Randomized Clinical Trials (RCT) have tested multi-component interventions that include these key components in AAs with T2DM. Behavioral Activation is a psychotherapeutic process whereby patients are encouraged to identify and schedule structured and enjoyable activities for behavior change that are likely to improve outcomes such as mood, behaviors and quality of life. A brief manualized behavioral activation treatment for depression (BATD), has been modified for diabetes. This study tests a multi-component, high intensity intervention that incorporates several strategies that have been shown to be effective in improving diabetes outcomes in AAs. Nurse case managers will use videoconferencing technology to deliver education, skills training and problem solving for diabetes via smartphones, an approach that has not been used previously in vulnerable and underserved ethnic minority populations.

Interventions

BEHAVIORALTECH DM-BAT

Multi-component, high intensity intervention, technology delivered, diabetes-modified behavioral activation treatment.

BEHAVIORALTECH DMBAT Active Comparator

Technology delivered diabetes education and home tele monitoring

BEHAVIORALTECH DMBAT Other

Technology delivered diabetes education

Sponsors

State University of New York at Buffalo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age ≥21 years * Clinical diagnosis of T2DM and HbA1c ≥8% at the screening visit; * Self-identified as AA * Subject must be willing to use the FORA monitoring system for 6 months * Subject must be willing to use the study assigned smartphone including videoconferencing, lifestyle monitoring and medication monitoring apps for 6 months * Subjects must be able to communicate in English * Subjects must have access to a landline or Ethernet for FORA data uploads for the study period.

Exclusion criteria

* Mental confusion on interview suggesting significant dementia * Participation in other diabetes clinical trials * Alcohol or drug abuse/dependency * Active psychosis or acute mental disorder * Life expectancy \<6 months.

Design outcomes

Primary

MeasureTime frameDescription
Change from Baseline Hemoglobin A1c (HbA1c) at 3 and 6 monthsbaseline, 3-months, 6-monthsChange from Baseline Hemoglobin A1c (HbA1c) at 3 and 6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026